Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Chronic Myeloid Leukemia (CML): early-phase trial registry
1 of 8 indexed Chronic Myeloid Leukemia (CML) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,176 of 28,707 conditions by registered trial count.
8 US clinical trials · 1 currently recruiting · #2,176 of 28,707 conditions by registered trial count
Chronic Myeloid Leukemia (CML): 8 US clinical trials tracked, 1 recruiting.
Chronic Myeloid Leukemia (CML) is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is National Heart, Lung, and Blood Institute (NHLBI), running 3 of these trials.
Enrollment posture brief
Registry condition chronic-myeloid-leukemia-cml
OPEN 1 | RECR 13% | LATE 0 | EARLY 7 | RANK #2176 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Acute Respiratory Infection (13% recruiting · 8 trials)
Chronic Myeloid Leukemia (CML) lists 1 open slots (13% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Chronic Myeloid Leukemia (CML) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Chronic Myeloid Leukemia (CML) is recruiting below its size-band peers.
1 of 8 indexed trials (12.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Chronic Myeloid Leukemia (CML) research.
National Heart, Lung, and Blood Institute (NHLBI) accounts for 3 of 8 trials (37.5%). 5 distinct sponsors appear on at least one study for this condition label.
-
Most Chronic Myeloid Leukemia (CML) trials plan to enrol fewer than 100 people.
Median target enrolment is 35 among the 8 trials that report a genuine target (sentinel values excluded). 6 of those (75%) plan for fewer than 100 participants.
-
Chronic Myeloid Leukemia (CML) research is mostly interventional.
7 interventional and 1 observational studies make up this index (87.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
8 total, page 1 of 1
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Ossium Health
NCT05589896
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
St. Jude Children's Research Hospital
NCT02790515
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
St. Jude Children's Research Hospital
NCT03849651
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
Diane George
NCT02061800
Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population
Bristol-Myers Squibb
NCT02363868
Natural Killer Cells and Bortezomib to Treat Cancer
National Heart, Lung, and Blood Institute (NHLBI)
NCT00720785
Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers
National Heart, Lung, and Blood Institute (NHLBI)
NCT00488592
Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy
National Heart, Lung, and Blood Institute (NHLBI)
NCT00433745
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Chronic Myeloid Leukemia (CML) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Chronic Myeloid Leukemia (CML) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Chronic Myeloid Leukemia (CML) page
8 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Chronic Myeloid Leukemia (CML) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Heart, Lung, and Blood Institute (NHLBI) sponsors the most Chronic Myeloid Leukemia (CML) trials on record, review their full trial history before evaluating a specific study. See National Heart, Lung, and Blood Institute (NHLBI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Chronic Myeloid Leukemia (CML) condition card totals 8 registered trials; most-linked intervention Cyclophosphamide; top US site state Tennessee. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.